Don't call me..., page-6

Then all they'd have to do is take their version of iPPS through the same path as PAR have taken Zilosul, and prove over years and years of clinical evidence that it has the same safety and efficacy profile, then go through the registration with the FDA to have their iPPS approved as the second Drug Master File (after Zilosul) and once they've spent a decade a tens of millions of dollars doing that - they can infringe PAR's patents in all of the major markets by selling it as relief for OA/BMEL. Not sure how i'll sleep tonight.